- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05649904
AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis (AFFECT)
Use of Active Fluid Exchange to Therapeutically Treat Intracranial Bleeding and Infection
The goal of this clinical trial is to evaluate efficacy and safety of evacuation of cerebrospinal fluid, blood, and harmful bacteria from the intraventricular, subdural and subarachnoid spaces by Active Controlled Irrigation and Drainage (IRRAflow) compared to Passive External Ventricular Drainage (EVD).
Subjects with intraventricular hemorrhage, subarachnoid hemorrhage, subdural bleeding, and ventriculitis will be randomized to receive the IRRAflow device or EVD device and followed for one month post-procedure to compare outcomes between the subject groups.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Victoria Adams
- Phone Number: 6146854484
- Email: victoria.adams@osumc.edu
Study Contact Backup
- Name: Patrick Youssef, MD
- Phone Number: 6143666590
- Email: patrick.youssef@osumc.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- The Ohio State University Wexner Medical Center
-
Contact:
- Victoria Adams
- Email: victoria.adams@osumc.edu
-
Contact:
- Megan Frost
- Email: megan.frost@osumc.edu
-
Principal Investigator:
- Patrick Youssef
-
Sub-Investigator:
- Shahid Nimjee
-
Sub-Investigator:
- Ciaran Powers
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years of age
- Need of drainage for one of the following underlying conditions: Intraventricular hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage, chronic subdural hematoma and ventriculitis
- Indication for active treatment evaluated by treating physician for underlying conditions; Intraventricular hemorrhage, subarachnoid hemorrhage, chronic subdural hematoma and ventriculitis
- Signed informed consent obtained by subject or Legally Authorized Representative
Exclusion Criteria:
- Subject has fixed and dilated pupils
- Pregnant women
- Presence of Moyamoya
- History or presence of clotting disorder.
- Platelet count less than 100,000, INR greater than 1.4
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IRRAflow with Active Fluid Exchange System (IRRAflow)
Subjects may be randomized to receive the IRRAflow with Active Fluid Exchange System (intervention) for intracranial pressure monitoring and for externally draining intracranial fluid as a means of reducing intracranial pressure.
|
IRRAflow® Active Fluid Exchange System is an intracranial drainage system intended for use by professional medical hospital personnel, trained and experienced in neurosurgical medical care. The intracranial pressure is kept at a safe level by draining excessive intracranial fluid. The system incorporates an irrigation support mechanism, used to irrigate the system in a controlled, programmed manner to minimize catheter occlusion. Additionally, a manual bolus can be given to facilitate keeping the catheter clear of occlusion or to clear the catheter of occlusion if one is present. This mechanism works by producing a bolus pulse using short periods of high flow (i.e. flow pulses).
Other Names:
|
Active Comparator: External Ventricular Drainage (EVD)
Subjects may be randomized to receive an External Ventricular Drain (control) for intracranial pressure monitoring and for externally draining intracranial fluid as a means of reducing intracranial pressure.
|
The External Ventricular Drain (EVD) is used standard of care at the study site for ventricular drainage.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of revision procedures for the IRRAflow and EVD/Drainage catheters
Time Frame: Immediately post-procedure
|
Immediately post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to clearance of blood or bacterial mass as measured by head CT scan
Time Frame: Immediately post-procedure
|
Immediately post-procedure
|
|
Rate of catheter-related infection
Time Frame: Immediately post-procedure
|
Immediately post-procedure
|
|
Length of ICU stay
Time Frame: Baseline
|
Baseline
|
|
Rate of shunt dependency
Time Frame: Immediately post-procedure
|
Immediately post-procedure
|
|
Indwell time of EVD/Drainage and IRRAflow Catheter
Time Frame: Immediately post-procedure
|
Immediately post-procedure
|
|
Mortality rates - intraprocedural and at 30 days
Time Frame: 30 days post subject discharge
|
30 days post subject discharge
|
|
Functional Status - at inclusion and 30 days
Time Frame: 30 days post subject discharge
|
The Modified Rankin Scale will be used to assess functional status.
The Modified Rankin Scale ranges from 0 (no disability) to 6 (death).
|
30 days post subject discharge
|
Functional Status - at inclusion and 30 days
Time Frame: 30 days post subject discharge
|
The Extended Glasgow Coma Scale will be used to assess functional status.
Results range from 1 (death) to 8 (upper good recovery).
|
30 days post subject discharge
|
Functional Status - at inclusion and 30 days
Time Frame: 30 days post subject discharge
|
The Barthel Index will be used to assess functional status.
Scores for this assessment tool range from 0 - 100, with a higher number indicating a better functional status.
|
30 days post subject discharge
|
Functional Status - at inclusion and 30 days
Time Frame: 30 days post subject discharge
|
The Stroke Impact Scale will be used to assess functional status.
Scores for this scale range from 0 - 100, with a higher number indicating a better functional status.
|
30 days post subject discharge
|
Functional Status - at inclusion and 30 days
Time Frame: 30 days post subject discharge
|
The EQ-VAS will be used to assess functional status.
Participants rate their health from 0 (worst imaginable health) to 100 (best imaginable health).
|
30 days post subject discharge
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Patrick Youssef, MD, Ohio State University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Craniocerebral Trauma
- Trauma, Nervous System
- Intracranial Hemorrhages
- Intracranial Hemorrhage, Traumatic
- Hemorrhage
- Subarachnoid Hemorrhage
- Cerebral Hemorrhage
- Hematoma
- Hematoma, Subdural
Other Study ID Numbers
- 2022H0197
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subarachnoid Hemorrhage
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingSubarachnoid Hemorrhage, Aneurysmal | Subarachnoid Hemorrhage, SpontaneousItaly
-
Assiut UniversityNot yet recruitingPost-Traumatic Subarachnoid Hemorrhage
-
Medical University InnsbruckRecruitingSubarachnoid Hemorrhage | Subarachnoid Hemorrhage, Aneurysmal | Aneurysmal Subarachnoid Hemorrhage | Vasospasm, CerebralAustria
-
IRCCS San RaffaeleFondazione Policlinico Universitario Agostino Gemelli IRCCS; Azienda Ospedaliera... and other collaboratorsRecruitingSubarachnoid Hemorrhage, Aneurysmal | Poor Grade Subarachnoid HemorrhageItaly
-
Methodist Health SystemRecruitingTraumatic Intracranial Subarachnoid HemorrhageUnited States
-
University of CalgaryUnknownIntraventricular Hemorrhage | Aneurysmal Subarachnoid HemorrhageCanada
-
Macmillan Research Group UKCenter for Applied Research & Education; SMS Medical College and HospitalCompletedTraumatic Subarachnoid Haemorrhage
-
University of Texas Southwestern Medical CenterRecruitingSubarachnoid Hemorrhage, AneurysmalUnited States
-
Milton S. Hershey Medical CenterRecruiting
-
Second Affiliated Hospital, School of Medicine,...RecruitingSubarachnoid Hemorrhage, AneurysmalChina
Clinical Trials on IRRAflow with Active Fluid Exchange System
-
Icahn School of Medicine at Mount SinaiIRRASRecruiting
-
CHU de Quebec-Universite LavalCompletedEpiretinal MembraneCanada
-
Twin Star Medical, Inc.United States Department of DefenseUnknownCompartment SyndromeUnited States
-
Seoul St. Mary's HospitalCompletedFluid Overload | Fluid LossKorea, Republic of
-
Samsung Medical CenterCompleted
-
CHU de Quebec-Universite LavalCompletedCataract | Complications | Macular Holes | Visual Acuity GainCanada
-
Memorial Sloan Kettering Cancer CenterCompleted
-
National Health Service, United KingdomSouthern Health and Social Care TrustCompleted
-
Florida State UniversityRecruiting
-
Increase-TechUniversity of Valladolid; University of Alicante; Hospital Clínico Universitario...Recruiting